|
Q4 2024
|
89 |
7,514,204 |
ASND, PCVX, JANX, RYTM
|
13F-HR
|
2/14/2025 |
000110465925014181 |
|
Q3 2024
|
81 |
8,673,579 |
ASND, PCVX, JANX, LEGN
|
13F-HR
|
11/14/2024 |
000110465924119034 |
|
Q2 2024
|
78 |
7,560,766 |
ASND, PCVX, JANX, LEGN
|
13F-HR
|
8/14/2024 |
000110465924089629 |
|
Q1 2024
|
1 |
61,347 |
CGON
|
NEW HOLDINGS
|
5/17/2024 |
000110465924063050 |
|
Q1 2024
|
75 |
7,798,795 |
ASND, PCVX, LEGN, JANX
|
13F-HR
|
5/15/2024 |
000110465924062062 |
|
Q4 2023
|
62 |
6,402,499 |
ASND, IMGN, PCVX, LEGN
|
13F-HR
|
2/14/2024 |
000110465924023984 |
|
Q3 2023
|
1 |
37,587 |
CTKB
|
NEW HOLDINGS
|
11/15/2023 |
000110465923118452 |
|
Q3 2023
|
65 |
5,042,131 |
ASND, LEGN, PCVX, IMGN
|
13F-HR
|
11/14/2023 |
000110465923118214 |
|
Q2 2023
|
54 |
5,296,462 |
ASND, LEGN, PCVX, DICE
|
13F-HR
|
8/14/2023 |
000110465923091405 |
|
Q1 2023
|
59 |
4,417,403 |
ASND, PCVX, DICE, ETNB
|
13F-HR
|
5/15/2023 |
000110465923060785 |
|
Q4 2022
|
70 |
4,930,699 |
ASND, PCVX, AVTE, DICE
|
13F-HR
|
2/14/2023 |
000110465923021847 |
|
Q3 2022
|
81 |
4,687,527 |
ASND, BIIB, CTKB, FORMA THERAPEUTICS HLDGS INC
|
13F-HR
|
11/14/2022 |
000110465922118654 |
|
Q2 2022
|
88 |
3,750,535 |
ASND, BIIB, CTKB, AVTE
|
13F-HR
|
8/15/2022 |
000110465922091331 |
|
Q1 2022
|
96 |
4,583,149 |
ASND, BIIB, AVTE, CTKB
|
13F-HR
|
5/16/2022 |
000110465922061386 |
|
Q4 2021
|
97 |
5,671,942 |
ASND, NVAX, ITOS, TVTX
|
13F-HR
|
2/14/2022 |
000110465922022807 |
|
Q3 2021
|
95 |
7,216,744 |
ASND, NVAX, ELYM, IVVD
|
13F-HR
|
11/15/2021 |
000110465921139249 |
|
Q2 2021
|
92 |
6,230,450 |
ASND, NVAX, FORMA THERAPEUTICS HLDGS INC, JANX
|
13F-HR
|
8/16/2021 |
000110465921106386 |
|
Q1 2021
|
82 |
6,631,817 |
ASND, NVAX, VOR, AVIR
|
13F-HR
|
5/17/2021 |
000110465921068149 |
|
Q4 2020
|
82 |
7,153,595 |
ASND, TGTX, NVAX, NKTX
|
13F-HR
|
2/16/2021 |
000110465921024161 |
|
Q3 2020
|
70 |
5,467,231 |
ASND, FORMA THERAPEUTICS HLDGS INC, CHEMOCENTRYX INC, PCVX
|
13F-HR
|
11/16/2020 |
000110465920125858 |
|
Q2 2020
|
57 |
5,131,829 |
ASND, FORMA THERAPEUTICS HLDGS INC, NVAX, CHEMOCENTRYX INC
|
13F-HR
|
8/14/2020 |
000110465920095562 |
|
Q1 2020
|
48 |
3,165,729 |
ASND, RARX, CHEMOCENTRYX INC, ARVN
|
13F-HR
|
5/15/2020 |
000110465920062663 |
|
Q4 2019
|
34 |
3,297,714 |
THOR, ASND, RARX, ARVN
|
13F-HR
|
2/14/2020 |
000110465920021928 |
|
Q3 2019
|
32 |
1,678,386 |
ASND, WVE, THOR, RARX
|
13F-HR
|
11/14/2019 |
000110465919064263 |
|
Q2 2019
|
25 |
1,862,830 |
ASND, WVE, ZGNX, RARX
|
13F-HR
|
8/14/2019 |
000114420419040093 |
|
Q1 2019
|
29 |
2,319,025 |
ASND, WVE, THOR, ZGNX
|
13F-HR
|
5/15/2019 |
000114420419026610 |
|
Q4 2018
|
25 |
1,717,985 |
WVE, ASND, THOR, ZGNX
|
13F-HR
|
2/14/2019 |
000114420419008235 |
|
Q3 2018
|
26 |
1,870,521 |
WVE, ASND, SLDB, ECYT
|
13F-HR
|
11/14/2018 |
000114420418059977 |
|
Q2 2018
|
27 |
1,540,247 |
WVE, ASND, SLDB, ECYT
|
13F-HR
|
8/14/2018 |
000114420418044712 |
|
Q1 2018
|
31 |
1,305,208 |
WVE, ASND, AVXS, MYOV
|
13F-HR
|
5/15/2018 |
000114420418028896 |
|
Q4 2017
|
27 |
1,195,149 |
WVE, ASND, AVXS, SAGE
|
13F-HR
|
2/14/2018 |
000114420418008963 |
|
Q3 2017
|
27 |
1,106,912 |
ASND, WVE, AVXS, BIOHAVEN PHARMACTL HLDG CO LTD
|
13F-HR
|
11/14/2017 |
000114420417059064 |
|
Q2 2017
|
22 |
871,430 |
ASND, WVE, AVXS, ACHN
|
13F-HR
|
8/14/2017 |
000114420417043212 |
|
Q1 2017
|
24 |
815,257 |
WVE, ASND, AVXS, ACHN
|
13F-HR
|
5/15/2017 |
000114420417027535 |
|
Q4 2016
|
26 |
687,184 |
WVE, ASND, AVXS, ACHN
|
RESTATEMENT
|
2/16/2017 |
000114420417009568 |
|
Q4 2016
|
1 |
18,660 |
MYOV
|
NEW HOLDINGS
|
2/16/2017 |
000114420417009569 |
|
Q3 2016
|
31 |
969,369 |
WVE, ACHN, ASND, AVXS
|
13F-HR
|
11/14/2016 |
000114420416134325 |
|
Q2 2016
|
32 |
722,235 |
WVE, ACHN, AXOVANT SCIENCES LTD, AVXS
|
13F-HR
|
8/15/2016 |
000114420416119492 |
|
Q1 2016
|
42 |
782,348 |
WVE, ACHN, AXOVANT SCIENCES LTD, ACRS
|
13F-HR
|
5/16/2016 |
000114420416102679 |
|
Q4 2015
|
37 |
1,010,538 |
ACHN, WVE, DYAX, AXOVANT SCIENCES LTD
|
13F-HR
|
2/16/2016 |
000114420416082766 |
|
Q3 2015
|
47 |
696,301 |
ACHN, AXOVANT SCIENCES LTD, DYAX, COLL
|
13F-HR
|
11/13/2015 |
000114420415065340 |
|
Q2 2015
|
59 |
994,105 |
AXOVANT SCIENCES LTD, ACHN, DYAX, SGMO calls
|
13F-HR
|
8/13/2015 |
000114420415049028 |
|
Q1 2015
|
57 |
1,006,949 |
SGMO calls, ACHN, DYAX, BCRX
|
RESTATEMENT
|
7/6/2015 |
000114420415041113 |
|
Q4 2014
|
51 |
930,497 |
SGMO calls, BCRX, ACHN, RGLS
|
13F-HR
|
2/17/2015 |
000114420415010101 |
|
Q3 2014
|
46 |
846,275 |
ACAD calls, DYAX, BCRX, ACHN
|
13F-HR
|
11/14/2014 |
000114420414068823 |
|
Q2 2014
|
28 |
989,267 |
ACHN, ACAD calls, DYAX, SGMO calls
|
13F-HR
|
8/14/2014 |
000114420414050172 |
|
Q1 2014
|
35 |
1,394,409 |
GILD puts, ACAD calls, SGMO calls, SGMO
|
13F-HR
|
5/15/2014 |
000114420414031040 |
|
Q4 2013
|
31 |
858,468 |
ACAD calls, ACHN, SGMO, TXMD
|
13F-HR
|
2/14/2014 |
000114420414009252 |